Vaccines are essential health resources

09.11.13 | By

To say that vaccines have changed the world for the better is a dramatic understatement. Vaccines have helped us to eradicate smallpox. They’ve helped to dramatically reduce the scourge of polio around the globe. They’ve prevented and controlled once deadly viruses like measles, rubella, influenzas and a host of other infectious and communicable conditions.  They are giving us new preventative and therapeutic tools to use in the fight against some cancers and other diseases.

U.S. Rep. Clyburn Explains How Clinical Trials Provide Opportunity to Address Health Disparities

09.10.13 | By

As you may know from a previous Catalyst post, late last month we unveiled a new report on Research in Your Backyard: Pharmaceutic

Team Hoyt Shares Hope

09.09.13 | By

I recently had the opportunity to speak to Team Hoyt, a father and son team, that have run over 1,000 endurance races together. Team Hoyt has been inducted into the Ironman Hall of fame,  honored with a life size bronze statue of their likeness by the start of the Boston marathon, and presented with the Jimmy V perseverance award.

Draft Guidance on Expedited Programs demonstrates FDA has broad regulatory flexibility to establish the safety and efficacy of innovative medicines to address unmet medical needs

09.09.13 | By

PhRMA has long supported the FDA’s appropriate use of innovative approaches and regulatory flexibility to establish the safety and efficacy of innovative medicines to address unmet medical needs.  We strongly supported the passage last year of the Food and Drug Administration Safety and Innovation Act (

Significance in Preventative Medicine

09.09.13 | By

Innovative research and development has led to revolutionary medical treatments and practices that have impacted how we think about preventative medicine. While colloquialisms like “an apple a day keeps the doctor away” still hold true, thanks to hardworking researchers, academics and individuals throughout the health care ecosystem, we now have an increasing selection of cutting-edge treatments that can protect us from some of the most debilitating diseases.

Prostate Cancer and Ovarian Cancer Awareness Month

09.05.13 | By

With the start of school and everyone resuming their normal routine, now is the time to schedule your regular doctor’s visit. Given the craziness of summer, health is often an afterthought -- but now is the time to make it a priority.

Finalizing the Agreement

08.30.13 | By

The 19th round of Trans-Pacific Partnership (TPP) negotiations in Brunei conclude today, and with countries looking to finalize the agreement by the end of this year, there is much to be done in the coming months.  

New Treatments for Patients

08.30.13 | By

Making a new treatment available to patients takes more than a decade and a billion dollars. Given the time and resources it takes to successfully bring a drug to market, the need for strong intellectual property (IP) protections in the U.S. and abroad has never been more important.

Kristin Van Goor

Kristin Van Goor is a Senior Director of Scientific and Regulatory Affairs at PhRMA.  She leads PhRMA’s activities on regulatory and science policy issues ranging from innovative biologics and biosimilars, information technology, benefit-risk assessment, and patient-focused drug development.  Kristin is a geneticist by training, having received her doctorate from Yale University and completing a postdoctoral fellowship in the Cancer Genetics Branch of the National Human Genome

PhRMA Conversations

08.29.13 | By

As we’ve previously noted on the Catalyst, medication adherence continues to be a serious challenge with significant consequences to patient health and costs associated with acute care, hospitalizations and surgery. Today, nearly 145 million Americans suffer from chronic disease, but only one-third take their medications as prescribed.


Subscribe to RSS - Opinion